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Abstract 
 
The emergence of the molecular triad osteoprotegerin (OPG)/Receptor Activator of 
NF-kB (RANK)/RANK Ligand (RANKL) has helped elucidate a key signalling pathway 
between stromal cells and osteoclasts. The interaction between RANK and RANKL plays a 
critical role in promoting osteoclast differentiation and activation leading to bone resorption. 
OPG is a soluble decoy receptor for RANKL that blocks osteoclast formation by inhibiting 
RANKL binding to RANK. The OPG/RANK/RANKL system has been shown to be 
abnormally regulated in several malignant osteolytic pathologies such as multiple myeloma, 
where enhanced RANKL expression (directly by tumour cells or indirectly by stromal bone 
cells or T-lymphocytes) plays an important role in associated bone destruction. By contrast, 
production of its endogenous counteracting decoy receptor OPG is either inhibited or too low 
to compensate for the increase in RANKL production. Therefore, targeting the 
OPG/RANK/RANKL axis may offer a novel therapeutic approach to malignant osteolytic 
pathologies. In animal models, OPG or soluble RANK were shown both to control 
hypercalcaemia of malignancy and the establishment and progression of osteolytic metastases 
caused by various malignant tumours. To this day, only one phase I study has been performed 
using a recombinant OPG construct that suppressed bone resorption in patients with multiple 
myeloma or breast carcinoma with radiologically confirmed bone lesions. RANK-Fc also 
exhibits promising therapeutic effects, as revealed in animal models of prostate cancer and 
multiple myeloma. If the animal results translate to similar clinical benefits in humans, using 
RANK-Fc or OPG may yield novel and potent strategies for treating patients with established 
or imminent malignant bone diseases and where standard therapeutic regimens have failed.  
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Introduction 
 
The invasion of bone tissue by a benign or malignant tumour, primary or secondary, rapidly 
affects the balance between bone resorption and apposition. In some rare cases, tumour 
development leads to osteoformation without osteolysis, as in some forms of osteosarcoma or 
osteoblastic metastasis predominating in patients with prostatic adenocarcinoma. In most 
cases, the skeletal manifestation of malignancy is focal osteolysis. This imbalance in favour of 
bone resorption can result from the acquisition of new cellular properties by bone cells : 
increase in the proteolytic activity, alteration in local or humoral factors expression. One 
hypothesis is that genomic instability of tumour cells (bone metastases, bone sarcoma, giant 
cell tumours) might cause mutations that affect critical cellular properties. Another hypothesis 
is the building of an environment favouring bone resorption (essential cyst)[1]. Whatever the 
causes and the mechanisms, tumour-induced osteolysis is responsible for high morbidity. 
Severe bone pain remains the first symptom, as revealed in the majority of benign tumours 
and in 60 to 70% of bone metastases, pathological fractures, nerve compression syndromes 
(paralysis) and profound hypercalcaemia (in secondary tumours only). Osteolysis must occur 
before tumour cells can grow and invade the mineralised bone. Although in vitro studies 
demonstrated that breast cancer cells can directly resorb bone [2], the majority of evidence 
shows that the primary mechanism responsible for bone destruction in patients with cancer is 
tumour-mediated stimulation of osteoclastic bone resorption. Osteoclasts appear to be the 
primary bone-resorbing cells both in normal and pathological states. Increased osteoclastic 
bone resorption results from both increased osteoclast generation and induction of pre-
existing osteoclast to resorb bone. Tumour products can either stimulate osteoclast formation 
locally in the bone microenvironment or systemically through production of hormones such as 
parathyroid hormone-related protein (PTH-rP), the mediator of the humoral hypercalcaemia 
of malignancy. Other factors produced by tumour cells that can stimulate osteoclastic bone 
resorption include interleukin-1 (IL-1), IL-6, tumour necrosis factor-alpha (TNF-α) and 
macrophage inflammatory protein-1-alpha (MIP-1α)[3]. These agents, released into the bone 
microenvironment, act on osteoblastic stromal cells to enhance the production of osteoclast 
activating factors. Most notable of these is Receptor Activator of NF-kB Ligand (RANKL), 
which is a recent addition to the TNF gene family. Ample data from the literature highlights 
the critical role of RANKL in mediating tumour-induced bone destruction, in both primary 
and secondary bone tumours. Therefore, the development of therapeutic agents disrupting the 
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interactions of RANKL and its cognate receptor RANK represents promising new options for 
the treatment of patients with primary and secondary bone tumours.  
 
I. Involvement of RANKL/OPG in malignant bone diseases 
RANKL is a potent osteoclastogenic factor that, in combination with macrophage colony-
stimulating factor (M-CSF), induces osteoclast formation in vitro. RANKL is expressed as a 
membrane-bound protein on the surface of osteoblasts, osteocytes and marrow stromal cells 
[4]. In addition, activated T cells secrete RANKL as a soluble molecule [5]. Furthermore, 
most osteotropic factors such as IL-1, IL-11, prostaglandin E2 and 1,25-(OH)2D3 induce 
osteoclast formation by binding to marrow stromal cells, which in turn express increased 
levels of soluble or membrane forms of RANKL. RANKL then binds to its receptor RANK, 
present at the surface of osteoclast precursors and mature osteoclasts, inducing osteoclast 
formation and activation [6]. RANKL activity can be blocked by the soluble decoy receptor 
osteoprotegerin (OPG), resulting in prevention of bone resorption [7]. OPG, a recently 
described  member of the TNF receptor superfamily, is produced by a lot of cell types, such as 
bone-marrow stromal cells and osteoblasts, and blocks the fusion/differentiation stage of 
osteoclast precursors, rather than the proliferation stage, by binding to RANKL. Thus, the 
RANKL/RANK/OPG system produced by the bone microenvironment represents important 
and final cytokines of osteoclast biology, the ratio RANKL to OPG regulating in fine the 
orientation to bone formation or bone resorption. In the case of tumour-associated osteolysis, 
several studies have implicated the cytokines RANKL and OPG as essential regulators of 
tumour-bone interactions (osteolytic bone metastases, humoral hypercalcaemia of 
malignancy) [8]. 
Modulation of RANKL and OPG expression has been reported in several bone tumours 
where osteolysis occurs (Table 1). In a prospective immunohistochemical study, Good et al.  
demonstrated that primary benign and malignant bone tumours and metastasis were positive 
for RANKL (13 cases of 16)[9]. More recently, Grimaud et al. (2003) demonstrated by RT-
PCR and ELISA that the RANKL/OPG ratio was significantly increased in patients suffering 
from severe tumour-associated osteolysis compared to healthy tissues [10]. Moreover in the 
same study, RANKL expression was demonstrated immunohistochemically in primary 
malignant bone tumours (osteosarcoma and chondrosarcoma) and in Giant Cell Tumor 
(Figure 1). OPG was shown to co-localize with RANKL, suggesting that OPG expression 
may reflect a homeostatic mechanism of the skeleton to counterbalance the increased bone 
resorption. 
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- Myeloma 
The OPG/RANKL system has been widely studied in multiple myeloma-induced 
osteolysis. Multiple myeloma (MM) is a plasma cell malignancy that develops in the bone 
marrow and characterized by the development of osteolytic bone lesions associated with bone 
pain, hypercalcemia and pathological fractures. Three cell types are involved in this pathology 
: myeloma cells, bone marrow stromal cells and osteoclasts. Several data from the literature 
have reported that myeloma cells are able to induce an imbalance in the OPG/RANKL system 
in bone environment, and that this is responsible for osteolysis observed in patients. 
Immunohistochemical staining of bone marrow biopsies from patients with MM shows an 
increase of RANKL and a reduction of OPG expression [11]. Roux et al. reported that 
RANKL is over-expressed in stromal cells at the interface of MM with normal bone marrow 
elements [12]. However, there is controversy as to whether myeloma cells directly express 
RANKL [11-17]. In addition to increasing RANKL expression, MM-infiltrated bone marrow 
exhibits decreased production of the natural RANKL inhibitor OPG. Serum OPG levels were 
shown to be reduced in patients with multiple myeloma with lytic bone disease [18,19]. Two 
mechanisms are involved in this process. First, cell-to-cell contacts between myeloma cells, 
bone marrow stromal cells and osteoblasts inhibit OPG expression and production by stromal 
cells, as evidenced by co-culture experiments [11,16]. Second, syndecan-1, a transmembrane 
proteoglycan that is highly expressed at the surface of myeloma cells, binds and sequesters 
OPG through interaction with the heparin-binding domain of the OPG protein [20]. OPG is 
thereby internalised and degraded within the lysosomal compartment of myeloma cells. Thus, 
inhibition of OPG production by myeloma cells, both at transcriptional and post-translational 
levels, is associated with increased expression of RANKL in MM and disrupts the 
RANKL/OPG ratio in favour of the osteoclastogenesis factor RANKL. In a recent study, 
Terpos et al. demonstrate that the RANKL/OPG ratio is increased in MM and correlates with 
markers of bone resorption, osteolytic lesions and markers of disease activity, thus confirming 
for the first time in humans the importance of RANKL/OPG in the development of bone 
disease [21]. The authors therefore propose soluble RANKL/OPG ratio as a predictive 
survival index in multiple myeloma. In another hematologic malignancy, adult T-cell 
leukaemia cells from patients with hypercalcaemia strongly expressed the transcripts of the 
RANKL gene and induced in vitro the differentiation of human hematopoietic precursor cells 
into osteoclasts in the presence of M-CSF [22]. Direct contact between adult T-leukaemia 
cells and hematopoietic precursor cells was essential for the differentiation, suggesting that T-
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leukaemia cells induce the differentiation of hematopoietic precursor cells to osteoclasts 
through RANKL expressed on their surface. 
 
- Skeletal metastases 
RANKL involvement is also demonstrated in the case of skeletal metastases secondary 
to breast and prostate carcinoma. Indeed, the development of osteolytic bone metastases and 
humoral hypercalcaemia of malignancy are frequent clinical complications of breast and 
prostate carcinoma, and both disorders involve an excessive activation of osteoclast via the 
RANKL-RANK interaction. Huang et al have investigated the expression of RANKL by in 
situ hybridisation and immunohistochemistry in the skeletal lesions of 16 patients with 
carcinomas that had metastasised to the bone [23]. Both RANKL mRNA and protein were 
present in more than 90% of metastatic tumour cells in adenocarcinoma lesions (from breast, 
prostate, lung or thyroid origin). With regard to the measurement of soluble RANKL, few 
studies have measured this ligand in the circulation of patients with malignant disease [24], 
although there is abundant evidence that RANKL mRNA is expressed in cells derived from 
the breast cancer stroma [25]. Results from this study and others suggest that the 
RANKL/OPG ratio is variable depending on the phenotype of the prostate cancer cells 
[26,27]. Other studies have reported that prostate cancer cells were shown to produce both 
OPG and RANKL, enabling then to influence bone metabolism through inhibition (OPG) and 
stimulation (RANKL) of osteoclastogenesis [28-30]. Immunohistochemical studies suggest 
that both OPG and RANKL are present in vivo in prostatic cancers, with higher levels of OPG 
detected in bone metastases than in primary tumours and metastases from non-osseous sites 
[29]. Few studies have determined OPG levels in patients with metastatic disease to the bone. 
In a recent study from Lipton et al, the serum OPG levels were measured in patients with 
solid tumours and metastatic diseases [19]. The results showed that, although some patients 
have significant levels of circulating OPG, these concentrations do not approach the level that 
would be expected to counterbalance the elevated RANKL production, thus suppressing 
osteoclast function. Jung et al. examined the serum level of OPG, in relation with the tumor 
dissemination, in patients with prostate cancer [31]. These authors showed that increased 
serum OPG is a marker of bone metastatic spread in prostate cancer patients. The same team 
recently studied the behaviour and diagnostic usefulness of RANKL and OPG in the serum of 
patients with prostate cancer [32]. While OPG was increased in patients with bone metastases, 
as previously demonstrated, RANKL levels did not differ among the control and prostate 
cancer groups. In this case, serum OPG but not RANKL indicates disrupted 
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osteoclastogenesis in patients with prostate cancer and bone metastatic spread and could be 
used as a marker for bone metastases. Thus, the OPG/RANKL ratio showed behaviour similar 
to that of OPG.  
OPG further affects cancer cells, suppressing TRAIL (Tumor necrosis factor-related 
apoptosis-inducing ligand)-induced tumour cell apoptosis by binding to TRAIL. This was 
demonstrated with conditioned medium from co-cultures of MG63 cells with myeloma cells, 
which had a reduced effect on TRAIL-induced apoptosis, reflecting the decreased 
concentrations of OPG in co-cultures of myeloma cells with bone cells [33]. From these 
experiments, OPG may be considered as a survival factor for myeloma cells. The same results 
and conclusions were reported in Holen’s study using prostate cancer cells : a strong negative 
correlation was observed between levels of endogenously produced OPG in the medium and 
the capacity of TRAIL to induce apoptosis in cells that produced high levels of OPG [30]. In 
relation with this activity, it has been hypothesized that the ability to produce OPG by cancer 
cells would confer them a survival advantage.  
 
- Giant Cell Tumour of bone 
RANKL/OPG involvement in bone tumours has also been demonstrated in Giant Cell 
Tumour (GCT) of bone, a rare primary osteolytic tumour characterized by massive bone 
destruction at the epiphysis of long bones. Histologically, it is characterized by a large 
number of multinucleated giant cells, macrophage-like and stromal-like mononuclear cells. 
There is no evidence that tumour cells themselves are capable of bone destruction. It appears 
instead that the tumour cells of GCT act by promoting osteoclastogenesis. However, the 
expression of OPG, RANK and RANKL seems to be cell type-dependent in GCT [34,35]. 
The ratio of RANKL and OPG gene expression in tumour cells may thus determine local 
osteoclastogenesis. Concurrently, the study of Miyamoto et al. confirm that spindle-shaped 
stromal cells secrete a soluble factor that could be soluble RANKL, which supports 
osteoclast-like cell formation in GCT [36]. RANKL was also shown to be expressed in 
chondroblastoma, where its involvement in osteoclastic giant cell recruitment had been 
suggested [37]. 
 Altogether, data from the literature highlights the RANKL/OPG ratio’s important role 
in malignant bone diseases. Normal stromal cells maintain the stable RANKL/OPG ratio that 
is required for normal bone remodelling. Stromal cells derived from GCT overexpress 
RANKL, which results in an increased RANKL/OPG ratio, which in turn results in an 
excessive development of large multinucleated osteoclasts. Myeloma and some forms of 
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breast carcinoma produce PTH-rP which induces RANKL and inhibits OPG production, thus 
resulting in an increased RANKL-to-OPG ratio that favours osteolysis and humoral 
hypercalcaemia of malignancy. By contrast, decreased or non modified RANKL and 
increased OPG production in prostate carcinoma results in a reduced RANKL/OPG ratio and 
may favour an osteoblastic tumour growth pattern.  
 
II. The vicious cycle  
Histological analysis of osteolytic bone metastases indicates that the bone destruction is 
mediated by the osteoclasts rather than directly by tumour cells. The interaction between 
tumour cells, tumour-derived humoral factors and the bone marrow microenvironment are 
crucial for the initiation and promotion of skeletal malignancies. These observations suggest a 
vicious cycle driving the formation of osteolytic bone tumours [38,39] (Figure 2) : tumour 
cells secrete soluble factors in bone (such as hormones, cytokines and growth factors), among 
them PTH-rP, which stimulates osteoclastic bone resorption through indirect RANKL 
production by osteoblastic stromal cells [40-45]. However, other data showed that tumour 
cells can produce themselves RANKL, acting directly on osteoclast differentiation and 
activation, as reported in multiple myeloma [14], prostate cancer [46], carcinoma cell lines 
[47] or human neuroblastoma [48]. RANKL expressed by stromal cells or directly by cancer 
cells can then bind to its cognate receptor RANK at the surface of osteoclast precursors and, 
in the presence of M-CSF, enhances the differentiation and fusion of these cells to produce 
functional multinucleated osteoclasts. Osteoclastic resorption in turn releases growth factors 
from the bone matrix, that can activate the tumour cells. In particular, Transforming Growth 
Factor-beta (TGF-β) is abundant in bone matrix and released as a consequence of osteoclastic 
bone resorption [49]. In addition to its rich stores of TGF-β, bone contains other growth 
regulatory factors that may act as tumour growth factors, including BMP (Bone 
Morphogenetic Proteins), heparin-binding fibroblast growth factors, and insulin-like growth 
factor I [50]. In this model, RANKL has been described as the final effector of 
osteoclastogenesis. The consequences of this vicious cycle are an increased tumour cell 
proliferation paralleled with an imbalance of bone formation/bone resorption ratio in favour 
of bone destruction. An experimental model of rat transplantable osteosarcoma [51] allows 
extending the “seed and soil” hypothesis to primary bone tumours, as development of local 
osteosarcoma tissue together with enhanced bone cortical destruction adjacent to the tumour 
can be observed in this model (Figure 2). 
 
 9 
III. New therapeutic strategies based on OPG or RANK-Fc use 
Osteolysis and tumour cell accumulation can be interrupted by inhibiting any of the 
vicious cycle’s member, including specifically neutralizing antibodies to PTH-rP and more 
effective osteoclast inhibitors. Advances in osteoclast biology and pathophysiology have 
helped towards defining putative therapeutic targets to attack tumour-induced osteolysis. 
Potential therapeutic agents are being studied, including RANKL antagonists (Table 2). Based 
on the studies of Simonet et al. and Yasuda et al., OPG has unambiguously been confirmed to 
act as a potent anti-resorptive molecule in vivo [7,52]. Therefore, as the majority of malignant 
bone diseases are characterized by enhanced bone resorption due to increased osteoclastic 
number and/or activity, it has been hypothesized that OPG also would be beneficial for 
treating animals with experimentally induced malignant bone diseases (Table 2). OPG was 
first shown to exhibit hypocalcaemic effects in normal mice and in hypercalcaemic nude mice 
carrying tumors associated with humoral hypercalcemia of malignancy [53]. OPG was then 
studied for its activity in a syngeneic tumour model of humoral hypercalcaemia of 
malignancy. It was shown to block tumour-induced increase in bone resorption and 
hypercalcaemia and to reduce osteoclast activity. However, it had no effect on tumour size, 
tumour-induced cachexia or PTH-rP levels [54].   
 
. Therapeutic applications of OPG 
In myeloma bone disease, OPG-Fc prevents the development of osteolytic bone lesions in 
5T2 and 5T33 multiple myeloma bearing animals [14,56,57]. These changes are associated 
with a preservation of the cancellous bone loss induced by myeloma cells and an inhibition of 
osteoclast formation. In an animal model of prostate cancer (CaP), CaP cells were injected 
both intratibially and subcutaneously in the same mice, followed by administration of OPG 
[46]. OPG completely prevented the establishment of mixed osteolytic/osteoblastic tibial 
tumours, but it had no effect on subcutaneous tumour growth. The same conclusions were 
reported by Yonou et al., indicating that human recombinant OPG decreased the CaP prostate 
burden selectively in bone, suppressed the progression of established tumour lesions and 
prevented the development of new lesions [58]. Honore et al. showed that OPG blocked bone 
cancer-induced skeletal destruction, skeletal pain and pain-related neurochemical 
reorganization of the spinal cord [59]. One year later, the same team demonstrated that 
administration of OPG halted further bone destruction, reduced ongoing and movement-
evoked pain and reversed several aspects of the neurochemical reorganization of the spinal 
cord in a mouse model of osteolytic 2472 sarcoma cells injected into the intramedullary space 
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of the femur [60].  In the case of GCT, which represents a paradigm for the direct stimulation 
of osteoclast formation and activity by tumour stromal cells, in vitro OPG treatment potently 
and dose-dependently inhibited resorption of bone slices by GCT and could also inhibit the 
formation of multinucleated osteoclasts from precursors within the GCT [61]. To date, a 
single study has been reported in patients with osteolytic bone tumours : a randomised, 
double-blind, double-dummy, active-controlled, single dose, dose escalation study was 
conducted to determine the safety and effect on bone resorption of recombinant OPG in 
patients with multiple myeloma or breast carcinoma with radiologically confirmed lytic bone 
lesions [62]. The results showed that a single dose of recombinant OPG suppressed bone 
resorption as indicated by a rapid, sustained and profound decrease of urinary NTX/creatinine 
in multiple myeloma and breast cancer patients, and that recombinant OPG was well 
tolerated.    
 
. Therapeutic applications of RANK-Fc 
As reported previously in the case of prostate cancer and multiple myeloma [30,33] 
but also in Jurkat cells [63], OPG prevents TRAIL-mediated apoptosis of tumour cells. It 
could be therefore hypothesized that the clinical use of OPG may prevent TRAIL-mediated 
apoptosis of tumour cells. Thus, methods for blocking RANKL activity, other than OPG, may 
be important. For this purpose, soluble RANK-Fc, was used in a model of prostate cancer and 
was shown to diminish tumour-induced osteoblastic lesions, decreased serum prostate-
specific antigen levels and tumour volume in the bone [64]. In myeloma, a recent study from 
Sordillo and Pearse reported that administration of RANK-Fc caused a marked reduction in 
tumour burden and serum paraprotein in the severe combined immunodeficiency (SCID)-hu-
MM mouse model of human MM [65]. This was associated to limited bone destruction, 
restoration of OPG and reduction in RANK-L expression in the xenograft. In another recent 
study, Oyajobi and Mundy tested the effectiveness of antagonists of RANKL and MIP-1alpha 
bioactivities (RANK-Fc and neutralizing monoclonal anti-MIP-1alpha antibody) on osteolysis 
and tumour burden in a mouse model in which murine myeloma 5TGM1 cells are injected 
intravenously into syngeneic mice [66]. The results demonstrated that RANK-Fc and anti-
MIP-1alpha antibody inhibited the development and progression of osteolytic lesions and 
significantly reduced tumour load assessed by serum monoclonal paraprotein titers. In a 
model of rat transplantable osteosarcoma, we developed new therapeutic approaches of 
primary bone tumours, and among them RANK-Fc delivery by gene therapy. The animals 
treated with the RANK-Fc construct exhibit higher bone apposition at the metaphysis of long 
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bones as shown by radiological analyses (Figure 3c), than controls treated with empty 
adenovirus (Figure 3b; Figure 3a : tumour controls). In this case, RANK-Fc inhibits the 
tumour induced-osteolysis but is not sufficient to decrease the tumour burden. In a therapeutic 
approach, RANK-Fc may be associated with anti-tumour drugs to stop both the tumour 
proliferation and the tumour-associated osteolysis. Overall, these studies demonstrate the 
effectiveness of RANK-Fc in inhibiting bone resorption in different models of malignant 
osteolytic pathologies and the upside of using RANK-Fc, which cannot interfere with TRAIL-
mediated cancer cell apoptosis. Another approach lies in using novel OPG-like 
peptidomimetics that restore bone loss in vivo by facilitating a defective RANKL-RANK 
receptor complex, thus modulating RANK-RANKL signalling pathways and altering the 
biological functions of RANKL-RANK receptor complex [67]. Therefore, these OPG derived 
small molecules can be used to develop more useful therapeutic agents in bone diseases. 
 
 
Conclusion 
Skeletal complications of malignancies are catastrophic clinical events. Understanding 
the molecular mechanisms responsible for osteoclast activation in osteolytic primary and 
secondary bone tumours should lead to development of novel therapeutic approaches for these 
highly morbid and potentially fatal pathologies. Several factors, including IL-1, IL-6, PTH-rP, 
RANK Ligand and MIP-1alpha have been involved in mediating the enhanced osteoclast 
formation and bone destruction in patients with neoplasia. The discovery and characterization 
of the RANKL/RANK/OPG system has implicated RANKL and OPG as important and final 
mediators of deregulated bone resorption, a characteristic feature of osteolytic bone 
metastases and humoral hypercalcemia of malignancy. Enhanced RANKL expression plays 
an important role in bone destruction in patients with myeloma. RANKL is either produced 
directly by tumour cells or its production (by stromal bone cells or T-lymphocytes) is induced 
indirectly by tumour cells through secretion of PTH-rP and other cytokines. By contrast, 
production of the endogenous counteracting decoy receptor OPG is either inhibited or 
inappropriately low to compensate for the increase in RANKL. 
In animal models, OPG or soluble RANK are able to control humoral hypercalcaemia 
of malignancy effectively, as well as the establishment and progression of osteolytic 
metastases caused by various malignant tumours, and to prevent cancer-induced skeletal pain 
and bone loss associated with immobilization. A first study assessing the beneficial effects of 
OPG in human multiple myeloma has been performed and reported, showing that the in vitro 
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effects of OPG can be extrapolated to the in vivo setting in MM patients. Beyond OPG, 
RANK-Fc exhibits promising therapeutic effects, as shown in animal models of prostate 
cancer and multiple myeloma. If the animal data translates into a similar clinical benefit in 
humans, RANK-Fc together with OPG may become novel potent strategies to treat patients 
with established or imminent malignant bone diseases in whom standard therapeutic regimens 
have failed.  
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Legends of the figures : 
 
Figure 1 : Osteolysis associated with primary bone tumours 
Osteosarcoma (a : human, b: rat) : intense remodelling activity (arrows : osteoclasts) on 
tumour tissue contact (star); c. GCT: multinucleated osteoclast-like giant cells (arrows) and 
mononucleated cells (mnc). Original magnification, X 40. 
 
Figure 2 : Schematic representation of the tumour cell proliferation and osteolysis vicious 
cycle.  
Tumour cells may release soluble mediators such as hormones, cytokines, growth factors that 
act on osteoblastic stromal cells. The stromal cells produce RANKL, which binds to its 
cognate receptor RANK expressed on osteoclast precursors, enhancing the formation of active 
osteoclasts that carry out bone resorption. Occasionally, tumour cells have also been reported 
to directly release a soluble form of RANKL. Active osteoclasts then release growth factors, 
cytokines or bone matrix components stored in the bone matrix that in turn activate tumour 
cell proliferation. The vicious cycle thus induces both tumour cell proliferation and bone 
resorption. 
 
Figure 3 : Radiographs of osteosarcoma-bearing Sprague-Dawley rats, treated or not with 
adeno (Ad)-RANK-Ig. 
Osteosarcoma tumours were implanted contiguous to the tibia of male Sprague-Dawley rats on 
day 0. Eighteen days after, the rats were injected in an intra-portal situation with empty 
adenovirus (b) or with Ad-RANK-Ig (c), and compared to controls (a). Note the intense bone 
apposition at the metaphysis of long bones in Ad-RANK-Ig treated rats (c). 
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Table 1 : Malignant metabolic bone diseases with involvement of the RANKL/OPG 
system  
 
 
Pathology references 
 
. Expression of RANKL by bone tumors 
. RANKL/OPG ratio is increased in severe osteolysis 
 
. RANKL/OPG expression in multiple myeloma 
. Disturbance in the OPG/RANKL balance in the bone marrow environment of 
myeloma cells 
. OPG in serum of patients with multiple myeloma 
. OPG may be a survival factor for human myeloma cells  
. RANKL/OPG ratio as a novel prognostic index in multiple myeloma 
 
. RANKL in adult T-cell leukaemia cells 
 
. RANKL expression in skeletal metastases 
. OPG and RANKL expression in the management of patients with skeletal 
metastases 
. RANKL expression by stromal cells in breast cancer 
. RANKL/OPG in breast cancer metastases 
. RANKL expressed by prostate cancer skeletal metastases  
. RANKL expressed by carcinoma cell lines 
. RANKL expressed in human neuroblastoma 
. OPG in human prostate cancer 
 
. RANKL in cancer-associated osteolytic lesions 
 
. RANKL/OPG in Giant Cell Tumor 
 
. RANKL expression in chondroblastoma 
 
. RANKL in hypercalcemia 
 
 
[9] 
[10] 
 
[12,13-15]  
 
[11,16,17] 
[18,19] 
[33] 
[21] 
 
[22] 
 
[23] 
 
[24] 
[25] 
[26] 
[27,46] 
[47] 
[48] 
[30] 
 
[25] 
 
[34-36] 
 
[37] 
 
[47] 
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Table 2 : Therapeutic strategies based on OPG/RANK/RANKL triad 
 
 
 
 
Pathology references 
 
. OPG prevents and reverses hypercalcemia malignancy 
. Inhibition of osteoclastogenesis and tumor growth in osteopetrotic mice 
by OPG 
  
. OPG inhibits osteolysis in multiple myeloma and increases survival in a 
murine model 
. OPG inhibits human prostate cancer burden in bone in an 
immunodeficient mice model 
. Serum OPG as a marker of bone metastatic spread in prostate cancer 
. OPG inhibits osteoclastogenesis and prevents prostate tumor growth 
 
. Single dose OPG in patients with bone metastases from multiple myeloma 
. Inhibition of cancer-induced skeletal destruction by OPG 
. OPG diminishes advanced bone cancer pain 
 
. RANK-Fc : a therapeutic antagonist for RANKL in myeloma 
. sRANK-Fc diminishes tumor volume in prostate cancer 
 
 
[53,54] 
[55] 
 
 
[56,57] 
 
[58] 
 
[31] 
[46] 
 
[62] 
[59] 
[60] 
 
[65,66] 
[64] 
 
 
 Table 1 :  Malignant metabolic bone diseases with involvement of the RANKL/OPG system and 
therapeutic strategies based on OPG/RANK/RANKL triad 
 
Pathology References 
RANKL and RANK expression in multiple myeloma  
Disturbance in the OPG/RANKL balance in the bone marrow 
environment of myeloma cells 
OPG may be a survival factor for human myeloma cells 
RANK-Fc: a therapeutic antagonist for RANK-L in myeloma 
Roux et al, 2002 ; Farrugia et al 2003 
Giuliani et al, 2001 ; Pearse et al, 2001 ; 
Giuliani et al, 2002 ; Yaccoby et al, 2002  
Shipman and Croucher, 2003 
Sordillo and Pearse, 2003 
Single dose in a single dose in patients with bone metastaes from 
multiple myeloma (clinical trial) OPG inhibits oteolysis in multiple 
myeloma and increases survival in a murine model 
RANKL/OPG ratio as a novel prognostic index in multiple myeloma 
Bekker et al, 2001  
Croucher et al, 2001 ; Vanderkerken et al, 2003 
 
Terpos et al, 2003 
RANKL as a prerequisite for cancer-associated osteolyic lesions Kitazawa et al, 2002 
OPG diminishes advanced bone cancer pain Luger et al, 2001 
Inhibition of cancer-induced skeletal destruction by OPG Honore et al, 2000 
RANKL expression in skeletal metastases Huang et al, 2002 
Expression of RANKL by bone tumors Good et al, 2002 
RANKL/OPG ratio is increased in severe osteolysis   
OPG and  RANKL expression in the management of patients with 
skeletal metastases 
Grimaud et al, in press 
Demers et al, 2003 
Inhibition of osteoclastogenesis and tumor growth in osteopetrotic 
mice by OPG 
Clohishy et al, 2000 
OPG inihibits human prostate cancer burden in bone in an 
immunodeficient mice model 
Yonou et al, 2003 
Serum OPG as a marker of bone metastatic spread in prostate cancer 
OPG inhibits osteoclastogenesis and prevent prostate tumor growth  
Jung et al, 2001  
Zhang et al, 2001 
OPG prevents ans reverses hypercalcemia malignancy  Akatsu et al, 1998; Capparelli et al, 2000 
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